
CURRICULUM VITAE

Prof. Dr. rer. nat. Margret Schottelius, geb. Leisner

Name: Schottelius, Margret Annemarie, geb. Leisner
Date of birth: December 28, 1972
Citizenship: German
Marital status: married, three children (born 2004, 2007, 2009)
Address: Laboratoire Translationnel des Sciences Radiopharmaceutiques
Département de médecine nucléaire et imagerie moléculaire et
Département d'oncologie
Centre Hospitalier Universitaire Vaudois (CHUV) et Université de
Lausanne (UNIL)
Agora, Bureau B25A/03/094
Rue du Bugnon 25A, CH-1011 Lausanne

+41 (0)79 556 0143 (MOBILE)
+41 (0)21 545 1120 (TEL DIRECT)

Email: Margret.Schottelius@chuv.ch

Scientific career

2019 Associate Professor for Translational Radiopharmaceutical Sciences at the **Centre Hospitalier Universitaire Vaudois (CHUV)**, Department of Nuclear Medicine and Molecular Imaging, and the **University of Lausanne (UNIL)**, Department of Oncology, Faculties of Biology and Medicine, Lausanne, Switzerland

2017 Appointment to titular Professor (Faculty of Medicine)

2010 - 2019 Senior research associate at the Chair of Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, **TU Munich** (Director: Prof. Dr. Hans-J. Wester)

2009 Habilitation in Nuclear Medicine/Radiopharmacy (Faculty of Medicine)

2002-2009 Post-doctoral fellowship at the Department of Nuclear Medicine, **TU Munich** (Director: M. Schwaiger)

1998-2002 PhD thesis at the Department of Nuclear Medicine, **TU Munich** (Director: M. Schwaiger), under the supervision of Prof. Dr. Hans-J. Wester (Faculties of Medicine and Chemistry) and Prof. Horst Kessler (Faculty of Chemistry)

1997-1998 Masters Thesis at the Laboratoire de Pharmacochimie Moléculaire of the **Université Louis Pasteur, Strasbourg, France**

1995-1997 Study of Chemistry, **Eidgenössische Technische Hochschule (ETH), Zurich, Switzerland** (Masters degree)

1994-1995 Full sponsorship at the **University of Rutgers**, the State University of New Jersey, New Brunswick, USA

1992-1994 Study of Chemistry, **University of Konstanz** (Bachelors degree)

Publications

78. Nonnekens J, Schottelius M. "Luke! Luke! Don't! It's a trap!"-spotlight on bias in animal experiments in nuclear oncology. *EJNMMI* **2020**, 47(5):1024-1026.
77. Hensbergen AW, van Willigen DM, van Beurden F, van Leeuwen PJ, Buckle T, Schottelius M, Maurer T, Wester HJ, van Leeuwen FWB. Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers? *Bioconjug Chem.* **2020**, 31(2):375-395.
76. van Leeuwen FWB, Schottelius M, Brouwer OR, Vidal-Sicart S, Achilefu S, Klode J, Wester HJ, Buckle T. Trending: Radioactive and Fluorescent Bimodal/Hybrid Tracers as Multiplexing Solutions for Surgical Guidance. *J. Nucl. Med.* **2020**, 61(1): 13-19.
75. Hensbergen AW, Buckle T, van Willigen DM, Schottelius M, Welling MM, van der Wijk FA, Maurer T, van der Poel HG, van der Pluijm G, van Weerden WM, Wester HJ, van Leeuwen FWB. Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen - Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction. *J. Nucl. Med.* **2019**, 61(2):234-241.
74. Hensbergen AW, van Willigen DM, Welling MM, van der Wijk FA, de Korne CM, van Oosterom MN, Schottelius M, Wester HJ, Buckle T, van Leeuwen FWB. Click Chemistry in the Design and Production of Hybrid Tracers. *ACS Omega* **2019**, 4(7):12438-12448.
73. Schottelius M, Ludescher M, Richter F, Kapp TG, Kessler H, Wester HJ. Validation of [¹²⁵I]CPCR4.3 as an investigative tool for the sensitive and specific detection of hCXCR4 and mCXCR4 expression in vitro and in vivo. *EJNMMI Res.* **2019**, 9(1):75.
72. Wester HJ, Schottelius M. PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy. *Semin. Nucl. Med.* **2019**, 49(4):302-312. (Review)
71. Horn T, Krönke M, Rauscher I, Haller B, Robu S, Wester HJ, Schottelius M, van Leeuwen FWB, van der Poel HG, Heck M, Gschwend JE, Weber W, Eiber M, Maurer T. Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. *Eur Urol.* **2019**, 76(4):517-523.
70. Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, van Leeuwen FWB, Haller B, Horn T, Heck MM, Gschwend JE, Schwaiger M, Wester HJ, Eiber M. ^{99m}Tc-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. *Eur. Urol.* **2019**, 75(4):659-666.
69. Schottelius M, Wurzer A, Wissmiller K, Beck R, Koch M, Gkorpas D, Notni J, Buckle T, van Oosterom MN, Steiger K, Ntziachristos V, Schwaiger M, van Leeuwen FWB, Wester HJ. Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer. *J. Nucl. Med.* **2019**, 60(1):71-78.
68. Nicolas GP, Morgenstern A, Schottelius M, Fani M. New Developments in Peptide Receptor Radionuclide Therapy. *J. Nucl. Med.* **2018** Dec 20 [Epub ahead of print]
67. Maurer T, van Leeuwen FWB, Schottelius M, Wester HJ, Eiber M. Entering the era of molecular-targeted precision surgery in recurrent prostate cancer. *J. Nucl. Med.* **2018** [Epub ahead of print]

66. Kircher M, Herhaus P, Schottelius M, Buck AK, Werner RA, Wester HJ, Keller U, Lapa C. CXCR4-directed theranostics in oncology and inflammation. *Ann. Nucl. Med.* **2018**, *32(8)*:503–511.
65. Wirtz M, Schmidt A, Schottelius M, Robu S, Günther T, Schwaiger M, Wester HJ. Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity. *EJNMMI Res.* **2018**, *8(1)*:84.
64. Schmidt A, Wirtz M, Färber SF, Osl T, Beck R, Schottelius M, Schwaiger M, Wester HJ. Effect of Carbohydrylation on the Theranostic Tracer PSMA I&T. *ACS Omega.* **2018**, *3(7)*:8278-8287.
63. Robu S, Schmidt A, Eiber M, Schottelius M, Günther T, Hooshyar Yousefi B, Schwaiger M, Wester HJ. Synthesis and preclinical evaluation of novel ¹⁸F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with ¹⁸F-DCFpyl and ¹⁸F-PSMA-1007. *EJNMMI Res.* **2018**, *8(1)*:30.
62. Habringer S, Lapa C, Herhaus P, Schottelius M, Istvanffy R, Steiger K, Slotta-Huspenina J, Schirbel A, Hänscheid H, Kircher S, Buck AK, Götze K, Vick B, Jeremias I, Schwaiger M, Peschel C, Oostendorp R, Wester HJ, Grigoleit GU, Keller U. Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics. *Theranostics* **2018**, *8(2)*:369-383.
61. Fang HY, Münch NS, Schottelius M, Ingermann J, Liu H, Schauer M, Stangl S, Multhoff G, Steiger K, Gerngroß C, Jesinghaus M, Weichert W, Kühl AA, Sepulveda AR, Wester HJ, Wang TC, Quante M. CXCR4 Is a Potential Target for Diagnostic PET/CT Imaging in Barrett's Dysplasia and Esophageal Adenocarcinoma. *Clin. Cancer Res.* **2018**, *24(5)*:1048-1061.
60. Buck AK, Stolzenburg A, Hänscheid H, Schirbel A, Lückerath K, Schottelius M, Wester HJ, Lapa C. Chemokine Receptor - directed Imaging and Therapy. *Methods* **2017**, *130*:63-71.
59. Rauscher I, Düwel C, Wirtz M, Schottelius M, Wester HJ, Schwamborn K, Haller B, Schwaiger M, Gschwend JE, Eiber M, Maurer T. Value of ¹¹¹In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. *BJU Int.* **2017**, *120(1)*:40-47.
58. Schottelius M, Osl T, Poschenrieder A, Hoffmann F, Beykan S, Hänscheid H, Schirbel A, Buck AK, Kropf S, Schwaiger M, Keller U, Lassmann M, Wester HJ. [¹⁷⁷Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. *Theranostics* **2017**, *7(9)*: 2350-2362.
57. Lapa C, Herrmann K, Schirbel A, Hänscheid H, Lückerath K, Schottelius M, Kircher M, Werner RA, Schreder M, Samnick S, Kropf S, Knop S, Buck AK, Einsele H, Wester HJ, Kortüm KM. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. *Theranostics* **2017**, *7(6)*:1589-1597.
56. Nonnekens J, Chatalic KL, Molkenboer-Kuening JD, Beerens CE, Bruchertseifer F, Morgenstern A, Veldhoven-Zweistra J, Schottelius M, Wester HJ, van Gent DC, van Weerden WM, Boerman OC, de Jong M, Heskamp S. ²¹³Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts. *Cancer Biother. Radiopharm.* **2017**, *32(2)*:67-73.
55. Hyafil F, Pelisek J, Laitinen I, Schottelius M, Mohring M, Döring Y, van der Vorst EP, Kallmayer M, Steiger K, Poschenrieder A, Notni J, Fischer J, Baumgartner C, Rischpler C, Nekolla SG, Weber C, Eckstein HH, Wester HJ, Schwaiger M. Imaging the Cytokine Receptor CXCR4 in Atherosclerotic Plaques with the Radiotracer ⁶⁸Ga-Pentixafor for PET. *J. Nucl. Med.* **2017**, *58(3)*, 499-506.

54. Brogsitter C, Hartmann H, Wunderlich G, Schottelius M, Wester HJ, Kotzerke J. Twins in spirit part IV - [¹⁷⁷Lu] high affinity DOTATATE. A promising new tracer for peptide receptor radiotherapy? *Nuklearmedizin*. **2017**, *56(1)*, 1-8.
53. Robu, S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester HJ. Preclinical Evaluation and First Patient Application of Tc-99m-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. *J. Nucl. Med.* **2017**, *58(2)*, 235-242.
52. Poschenrieder A, Schottelius M, Schwaiger M, Wester HJ. Preclinical evaluation of [⁶⁸Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo - a comparison to [⁶⁸Ga]pentixafor. *EJNMMI Res.* **2016**, *6(1)*, 70.
51. Poschenrieder A, Schottelius M, Schwaiger M, Kessler H, Wester HJ. The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity. *EJNMMI Res.* **2016**, *6(1)*, 36.
50. Maurer T, Schwamborn K, Schottelius M, Wester HJ, Schwaiger M, Gschwend JE, Eiber M. PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer. *Clin. Genitourin. Cancer.* **2016**, *14(5)*, e549-e552.
49. Rauscher I, Maurer T, Souvatzoglou M, Beer AJ, Vag T, Wirtz M, Weirich G, Wester HJ, Gschwend JE, Schwaiger M, Schottelius M, Eiber M. Inpatient Comparison of ¹¹¹In-PSMA I&T SPECT/CT and Hybrid ⁶⁸Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer. *Clin. Nucl. Med.* **2016**, *41(9)*, e397-402.
48. Herhaus P, Habringer S, Philipp-Abbrederis K, Vag T, Gerngross C, Schottelius M, Slotta-Huspenina J, Steiger K, Altmann T, Weißer T, Steidle S, Schick M, Jacobs L, Slawska J, Müller-Thomas C, Verbeek M, Subklewe M, Peschel C, Wester HJ, Schwaiger M, Götze K, Keller U. Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. *Haematologica.* **2016**, *101(8)*, 932-940.
47. Heck MM, Retz M, D'Alessandria C, Rauscher I, Scheidhauer K, Maurer T, Storz E, Janssen F, Schottelius M, Wester HJ, Gschwend JE, Schwaiger M, Tauber R, Eiber M. Systemic Radioligand Therapy with ¹⁷⁷Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. *J. Urol.* **2016**, *196(2)*, 382-391.
46. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ. ¹⁷⁷Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. *J. Nucl. Med.* **2016**, *57(7)*, 1006-1013.
45. Poschenrieder A, Osl T, Schottelius M, Hoffmann F, Wirtz M, Schwaiger M, Wester HJ. First ¹⁸F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo. *Tomography.* **2016**, *2(2)*, 85-93.
44. Rischpler C, Nekolla SG, Kossmann H, Dirschinger RJ, Schottelius M, Hyafil F, Wester HJ, Laugwitz KL, Schwaiger M. Upregulated myocardial CXCR4-expression after myocardial infarction assessed by simultaneous GA-68 pentixafor PET/MRI. *J. Nucl. Cardiol.* **2016**, *23(1)*, 131-133.
43. Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, Haenscheid H, Lueckerath K, Schreder M, Bluemel C, Knott M, Keller U, Schirbel A, Samnick S, Lassmann M, Kropf S, Buck A, Einsele H, Wester HJ, Knop S. First-in-man experience of CXCR4-directed endoradiotherapy with ¹⁷⁷Lu- and ⁹⁰Y-labelled pentixather in advanced stage multiple myeloma with extensive intra- and extramedullary disease. *J. Nucl. Med.* **2016**, *57(2)*, 248-251.

42. Chatalic KL, Heskamp S, Konijnenberg M, Molkenboer-Kueneen JD, Franssen GM, Clahsen-van Groningen MC, Schottelius M, Wester HJ, van Weerden WM, Boerman OC, de Jong M. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. *Theranostics*. **2016**, *6(6)*, 849-861.
41. Schottelius M, Wirtz M, Eiber M, Maurer T, Wester HJ. [¹¹¹In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. *EJNMMI Res*. **2015**, *5(1)*, 68.
40. Schottelius M, Konrad M, Osl T, Poschenrieder A, Wester HJ. An optimized strategy for the mild and efficient solution phase iodination of tyrosine residues in bioactive peptides. *Tetrahedron Lett*. **2015**, *56(47)*, 6602-6605.
39. Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, Kübler H, Thalgott M, Navab N, Schwaiger M, Wester HJ, Gschwend J, Eiber M. Prostate-specific Membrane Antigen-radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. *Eur. Urol*. **2015**, *68(3)*, 530-534.
38. Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, Kulkarni HR, Lassmann M, Klette I, Eiber M, Schwaiger M, Wester HJ. Ga-68- and Lu-177-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. *J. Nucl. Med*. **2015**, *56(8)*, 1169-1176.
37. Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, Eberlein U, Beykan S, Lapa C, Riedmiller H, Krebs M, Kropf S, Schirbel A, Buck AK, Lassmann M. Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy. *J. Nucl. Med*. **2015**, *56(6)*, 855-861.
36. Schottelius M, Simecek J, Hoffmann F, Willibald M, Schwaiger M, Wester HJ. Twins in spirit - episode I: comparative preclinical evaluation of [Ga-68]DOTATATE and [Ga-68]HA-DOTATATE. *EJNMMI Res*. **2015**, *5*, 22.
35. Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Lückerath K, Pietschmann E, Habringer S, Gerngross C, Franke K, Rudelius M, Schirbel A, Lapa C, Schwamborn K, Steidle S, Hartmann E, Rosenwald A, Kropf S, Beer AJ, Peschel C, Einsele H, Buck AK, Schwaiger M, Götze K, Wester HJ, Keller U. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. *EMBO Mol. Med*. **2015**, *7(4)*, 477-487.
34. Herrmann K, Lapa C, Wester HJ, Schottelius M, Schiepers C, Eberlein U, Bluemel C, Keller U, Knop S, Kropf S, Schirbel A, Buck AK, Lassmann M. Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe Ga-68-Pentixafor. *J. Nucl. Med*. **2015**, *56(3)*, 410-416.
Volume: 56
33. Wester HJ, Keller U, Schottelius M, Beer A, Philipp-Abbrederis K, Hoffmann F, Simecek J, Gerngross C, Lassmann M, Herrmann K, Pellegata N, Rudelius M, Kessler H, Schwaiger M. Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging. *Theranostics* **2015**, *5(6)*, 618-630.
32. Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester HJ. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. *EJNMMI Res* **2014**, *4*, 63.

31. Neubauer S, Rechenmacher F, Brimioulle R, Di Leva FS, Bochen A, Sobahi TR, Schottelius M, Novellino E, Mas-Moruno C, Marinelli L, Kessler H. Pharmacophoric Modifications Lead to Superpotent $\alpha\beta 3$ Integrin Ligands with Suppressed $\alpha 5\beta 1$ Activity. *J. Med Chem.* **2014**, *57(8)*, 3410-3417.
30. Hartmann H, Freudenberg R, Oehme L, Zöphel K, Schottelius M, Wester HJ, Wunderlich G, Kotzerke J, Brogsitter C. Dosimetric measurements of Ga-68-High Affinity DOTATATE Twins in spirit - part III. *Nuklearmedizin – Nuclear Medicine* **2014**, *53(5)*, 211-216.
29. Brogsitter C, Zöphel K, Hartmann H, Schottelius M, Wester HJ, Kotzerke J. Twins in spirit part II: DOTATATE and high-affinity DOTATATE-the clinical experience. *Eur. J. Nucl. Med. Mol. Imaging* **2014**, *41(6)*, 1158-1165.
28. Brogsitter C, Schottelius M, Zophel K, Kotzerke J, Wester HJ. Twins in spirit: DOTATATE and high-affinity DOTATATE. *Eur. J. Nucl. Med. Mol. Imaging* **2013**, *40(11)*, 1789.
27. Shen Y, Schottelius M, Zelenka K, De Simone M, Pohle K, Kessler H, Wester HJ, Schmutz P, Alberto R. Orthogonally Protected Artificial Amino Acid as Tripod Ligand for Automated Peptide Synthesis and Labeling with $[^{99m}\text{Tc}(\text{OH}_2)_3(\text{CO})_3]^+$. *Bioconj. Chem.* **2013**, *24(1)*, 26-35.
26. Demmer O, Frank AO, Hagn F, Schottelius M, Marinelli L, Cosconati S, Brack-Werner R, Kremb S, Wester HJ, Kessler H. A conformationally frozen peptoid boosts CXCR4 affinity and anti-HIV activity. *Angew. Chemie, Int. Ed.* **2012**, *51(32)*, 8110-8113.
25. Gourni E, Demmer O, Schottelius M, D'Alessandria C, Schulz S, Dijkgraaf I, Schumacher U, Schwaiger M, Kessler H, Wester HJ. PET of CXCR4 expression by a ^{68}Ga -labeled highly specific targeted contrast agent. *J. Nucl. Med.* **2011**, *52(11)*, 1803-1810.
24. Schottelius M, Wester HJ. Molecular imaging targeting peptide receptors (Review). *Methods* **2009**, *48(2)*, 161-177.
23. Hultsch C, Schottelius M, Auernheimer J, Alke A, Wester HJ. ^{18}F -Fluoroglucosylation of peptides, exemplified on *cyclo*(RGDfK). *Eur. J. Nucl. Med. Mol. Imaging* **2009**, *36(9)*, 1469-1474.
22. Schottelius M, Laufer B, Kessler H, Wester HJ. Ligands for mapping $\alpha\text{v}\beta 3$ -integrin expression in vivo (Review). *Acc. Chem. Res.* **2009**, *42(7)*, 969-980.
21. Schottelius M, Berger S, Poethko T, Schwaiger M, Wester HJ. Development of novel ^{68}Ga - and ^{18}F -labeled GnRH-I analogues with high GnRHR-targeting efficiency. *Bioconj. Chem.* **2008**, *19(6)*, 1256-1268.
20. Demmer O, Dijkgraaf I, Schottelius M, Wester HJ, Kessler H. Introduction of functional groups into peptides via N-alkylation. *Org. Lett.* **2008**, *10(10)*, 2015-2018.
19. Schlapschy M, Theobald I, Mack H, Schottelius M, Wester HJ, Skerra A. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. *PEDS* **2007**, *20(6)*, 273-284.
18. Knör S, Modlinger A, Poethko T, Schottelius M, Wester HJ. Synthesis of novel 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) derivatives for chemoselective attachment to unprotected polyfunctionalized compounds. *Chem. Eur. J.* **2007**, *13(21)*, 6082-6090.

17. Auernheimer J, Haubner R, Schottelius M, Wester HJ, Kessler H. Radio-Analytical Determination of the Coating Efficiency of Cyclic RGD Peptides. *Helv. Chim. Acta* **2006**, *89* (5), 833-840.
16. Meisetschlager G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M, Herz M, Wester HJ, Schwaiger M. Gluc-Lys(¹⁸F)FP-TOCA PET in Patients with SSTR-Positive Tumors: Biodistribution and Diagnostic Evaluation Compared with [¹¹¹In]DTPA-Octreotide. *J. Nucl. Med.* **2006**, *47*(4), 566-573.
15. Bruus-Jensen K, Poethko T, Schottelius M, Hauser A, Schwaiger M, Wester HJ. Chemoselective hydrazone formation between HYNIC-functionalized peptides and ¹⁸F-fluorinated aldehydes. *Nucl. Med. Biol.* **2006**, *33*(2), 173-183.
14. Vaidyanathan G, Affleck DJ, Schottelius M, Wester H, Friedman HS, Zalutsky MR. Synthesis and Evaluation of Glycosylated Octreotate Analogues Labeled with Radioiodine and ²¹¹At via a Tin Precursor. *Bioconjug. Chem.* **2006**, *17*(1), 195-203.
13. Stahl A, Meisetschlager G, Schottelius M, Bruus-Jensen K, Wolf I, Scheidhauer K, Schwaiger M. [¹²³I]Mtr-TOCA, a radioiodinated and carbohydrate analogue of octreotide: scintigraphic comparison with [¹¹¹In]octreotide. *Eur J Nucl Med Mol Imaging* **2006**, *33*(1), 45-52.
12. Schottelius M, Rau F, Reubi JC, Schwaiger M, Wester HJ. Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogs by variation of peptide net charge and carbohydrate chemistry. *Bioconj. Chem.* **2005**, *16*(2), 429-437.
11. Schottelius M, Reubi JC, Schwaiger M, Wester HJ. N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr³-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo. *J. Med. Chem.* **2005**, *48*(8), 2778-2798.
10. Poethko T, Schottelius M, Thumshirn G, Herz M, Haubner R, Henriksen G, Kessler H, Schwaiger M, Wester HJ. Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. *Radiochim. Acta* **2004**, *92* (4-6), 317-328.
9. Henriksen G, Schottelius M, Poethko T, Hauser A, Wolf I, Schwaiger M, Wester HJ. Proof of principle for the use of ¹¹C-labelled peptides in tumor diagnosis with PET. *Eur. J. Nucl. Med. Mol. Imaging*, **2004**, *31*(12), 1653-1657.
8. Wester HJ, Schottelius M, Poethko T, Bruus-Jensen K, Schwaiger M. Radiolabelled carbohydrate somatostatin analogs: a brief review of the current status. *Cancer Biother. Radiopharm.*, **2004**, *19*(2), 231-244.
7. Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M, Henriksen G, Kessler H, Schwaiger M, Wester HJ. Two-step methodology for high-yield routine radiohalogenation of peptides: ¹⁸F-labelled RGD- and octreotide analogs. *J. Nucl. Med.*, **2004**, *45*(5), 892-902.
6. Schottelius M, Poethko T, Herz M, Kessler H, Schwaiger M, Wester HJ. First ¹⁸F-labelled tracer suitable for routine clinical imaging of sst-receptor expressing tumors using positron emission tomography. *Clin. Cancer Res.* **2004**, *10*(11), 3593-3606.
5. Schottelius M, Schwaiger M, Wester HJ. Rapid and high-yield solution phase synthesis of DOTA-Tyr³-octreotide and DOTA-Tyr³-octreotate using unprotected DOTA. *Tetrahedron Lett.* **2003**, *44* (11), 2393 – 2396.

4. Vaidyanathan G, Friedman HS, Schottelius M, Wester HJ, Zalutsky MR. Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. *Clin. Cancer Res.* **2003**, 9(5), 1868-1876.
3. Wester HJ, Schottelius M, Scheidhauer K, Meisetschläger G, Herz M, Rau F, Reubi JC, Kimmich T, Arnold W, Schwaiger M. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel ¹⁸F-labelled, carbohydrate analogue of octreotide. *Eur. J. Nucl. Med. Mol. Imaging* **2003**, 30(1), 117-122.
2. Schottelius M, Wester HJ, Reubi JC, Senekowitsch-Schmidtke R, Schwaiger M. Improvement of Pharmacokinetics of radioiodinated Tyr³-octreotide by Conjugation with Carbohydrates. *Bioconj. Chem.* **2002**, 13(5), 1021-1030.
1. Wester HJ, Schottelius M, Scheidhauer K, Reubi JC, Wolf I, Schwaiger M. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydrate on the pharmacokinetics. *Eur. J. Nucl. Med. Mol. Imaging* **2002**, 29(1), 28-38.

Book Chapters

1. Wester HJ, Schottelius M, 2006, "Fluorine-18 labeling of peptides", In: PET Chemistry, The driving force in Molecular Imaging. PA Schubiger, L. Lehmann, M. Wiebe (editors), p79-112, Springer Verlag, ISBN 13-978-3-540-32623-6
2. Wester HJ, Schottelius M, 2007, „Radiopharmaka für die nukleare Onkologie“, in: Nuklearmedizinische Onkologie. BJ. Krause, A. Buck, M. Schwaiger (editors), p87-106, Verlagsgruppe Hüthig Jehle Rehm, ISBN 978-3-609-76308-8
3. Dijkgraaf I, Wester HJ, 2008, "Peptides, Multimers and Polymers", In: Handbook of Experimental Pharmacology, Molecular Imaging II; W. Semmler, M. Schwaiger (editors), p61-92, Springer Verlag, ISBN 978-3-540-77449-5
4. Dijkgraaf I, Schottelius M, Wester HJ, 2008. "F-18 labeling of peptides and proteins". In: Recent Advances of Bioconjugation Chemistry in Molecular Imaging, Chen X (editor); ISBN: 978-81-308-0210-7
5. Auernheimer J, Schottelius M, Wester HJ, 2008, "Carbohydration of radiolabeled peptides", In: Recent Advances of Bioconjugation Chemistry in Molecular Imaging, Chen X (editor); ISBN: 978-81-308-0210-7
6. Schottelius M, "Peptide Radiopharmaceuticals", in: Munich Molecular Imaging Handbook Series, Vol 1. Pharmaceutical Radiochemistry (I), Wester HJ (editor); ISBN 978-3-9813523-0-6

Patents

WO/2020/053255A1, EP/2019/074195W: "Therapeutic and diagnostic agents for cancer"
 Inventors: T. Osl, M. Schottelius, H.J. Wester.

WO/2020/053256A1, EP/2019/074196W: "CXCR4-targeted diagnostic and therapeutic agents with reduces species selectivity"
 Inventors: T. Kapp, H. Kessler, T. Osl, M. Schottelius, H.J. Wester.

WO/2015/185162A1, EP2014/061875: „Modified cyclopentapeptides and uses thereof“.
 Inventors: H.J. Wester, M. Schottelius, T. Osl, A. Poschenrieder, M. Willibald.

WO/2011/131735, EP2011/056358: „Cyclopentapeptide derivatives and uses thereof“.
Inventors: O. Demmer, H. Kessler, H.J. Wester, M. Schottelius, I. Dijkgraaf, A. Buck.

WO02085418A2, EP01201466A: „Tc and Re labeled radioactive glycosylated octreotate derivatives“.
Inventors: M. Schottelius, M. Schwaiger, H.J. Wester.